Full article view2017-09-21T12:08:00+00:00
Back to News & Insights »

HCEI and PIE: Is it time for pharma to be proactive in the argument over cost-effectiveness?

 

The FDA and the US Department of Health and Human Services published final guidance on the presentation of health care economic information (HCEI) and preapproval information exchange (PIE). This is a new opportunity for manufacturers to engage with payers around cost-effectiveness. Precision’s Jeremy Schafer views it from the manufacturer’s perspective in his article for KNect365.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK